STIM Stock Analysis: Neuronetics | NASDAQ

Medical Devices | NASDAQ, USA | Market Cap: 164m USD | 12M Return: -63.6% | US64131A1051 | Charts, Fundamentals & Technical Analysis

Magnetic Stimulation, Depression Therapy, Brain Treatment, Psychiatric Devices
Total Rating 18
Safety 40
Buy Signal -0.32
Medical Devices
Industry Rotation: -1.2
Market Cap: 164M
Avg Turnover: 3.08M
Risk 3d forecast
Volatility103%
VaR 5th Pctl15.1%
VaR vs Median-9.71%
Reward TTM
Sharpe Ratio-0.12
Rel. Str. IBD4.2
Rel. Str. Peer Group5.2
Character TTM
Beta1.292
Beta Downside0.679
Hurst Exponent0.526
Drawdowns 3y
Max DD87.33%
CAGR/Max DD0.08
CAGR/Mean DD0.15
EPS (Earnings per Share) EPS (Earnings per Share) of STIM over the last years for every Quarter: "2021-06": -0.29, "2021-09": -0.31, "2021-12": -0.29, "2022-03": -0.41, "2022-06": -0.39, "2022-09": -0.28, "2022-12": -0.3, "2023-03": -0.38, "2023-06": -0.17, "2023-09": -0.33, "2023-12": -0.19, "2024-03": -0.27, "2024-06": -0.33, "2024-09": -0.44, "2024-12": -0.33, "2025-03": -0.21, "2025-06": -0.15, "2025-09": -0.13, "2025-12": -0.1, "2026-03": -0.15,
Last SUE: 0.26
Qual. Beats: 0
Revenue Revenue of STIM over the last years for every Quarter: 2021-06: 14.203, 2021-09: 13.799, 2021-12: 15.022, 2022-03: 14.181, 2022-06: 16.329, 2022-09: 16.498, 2022-12: 18.198, 2023-03: 15.54, 2023-06: 17.61, 2023-09: 17.884, 2023-12: 20.314, 2024-03: 17.417, 2024-06: 16.45, 2024-09: 18.53, 2024-12: 22.493, 2025-03: 31.975, 2025-06: 38.108, 2025-09: 37.297, 2025-12: 41.777, 2026-03: 34.454,
Rev. CAGR: 37.39%
Rev. Trend: 91.4%
Last SUE: 0.14
Qual. Beats: 0

Warnings

Interest Coverage Ratio Critical
Altman Z'' In Financial Distress Zone

Tailwinds

No distinct edge detected

Seasonality

Not enough history
Description: STIM Neuronetics

Neuronetics, Inc. (STIM) is a commercial-stage medical technology company focused on non-invasive treatments for neurohealth disorders. Its primary product, the NeuroStar Advanced Therapy System, utilizes transcranial magnetic stimulation (TMS) to treat adult patients diagnosed with major depressive disorder (MDD) who have failed to achieve satisfactory improvement from prior antidepressant medication.

The company operates within the Health Care Equipment sector, utilizing a direct-to-provider business model by selling systems and recurring treatment sessions to psychiatric practices. TMS technology represents a significant shift in mental health care, offering a non-systemic alternative to traditional pharmaceuticals, which often carry high systemic side-effect profiles.

Investors can evaluate detailed valuation metrics and historical performance for STIM on ValueRay. The company focuses on expanding the clinical indications for its TMS platform to increase its total addressable market within the outpatient mental health space.

Headlines to Watch Out For
  • NeuroStar system utilization rates drive recurring revenue through per-treatment session fees
  • Insurance reimbursement coverage expansion for TMS therapy increases patient access and volume
  • Sales force productivity and psychiatrist adoption rates dictate capital equipment placement growth
  • High interest rates impact customer ability to finance new system purchases
  • Strategic acquisition of Greenbrook TMS consolidates market share and improves operating leverage
Piotroski VR-10 (Strict) 2.5
Net Income: -37.1m TTM > 0 and > 6% of Revenue
FCF/TA: -0.11 > 0.02 and ΔFCF/TA 15.43 > 1.0
NWC/Revenue: 12.46% < 20% (prev 40.05%; Δ -27.60% < -1%)
CFO/TA -0.10 > 3% & CFO -12.8m > Net Income -37.1m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.67 > 1.5 & < 3
Outstanding Shares: last quarter (69.6m) vs 12m ago 13.22% < -2%
Gross Margin: 47.96% > 18% (prev 63.51%; Δ -15.55% > 0.5%)
Asset Turnover: 113.4% > 50% (prev 63.00%; Δ 50.41% > 0%)
Interest Coverage Ratio: -3.45 > 6 (EBIT TTM -29.0m / Interest Expense TTM 8.41m)
Altman Z'' -12.54
A: 0.15 (Total Current Assets 47.2m - Total Current Liabilities 28.3m) / Total Assets 125.4m
B: -3.74 (Retained Earnings -469.6m / Total Assets 125.4m)
C: -0.22 (EBIT TTM -29.0m / Avg Total Assets 133.7m)
D: 0.12 (Book Value of Equity 13.3m / Total Liabilities 108.4m)
Altman-Z'' = -12.54 = D
Beneish M -2.67
DSRI: 0.35 (Receivables 16.1m/26.9m, Revenue 151.6m/89.4m)
GMI: 1.32 (GM 63.51% / 47.96%)
AQI: 1.19 (AQ_t 0.41 / AQ_t-1 0.34)
SGI: 1.70 (Revenue 151.6m / 89.4m)
TATA: -0.19 (NI -37.1m - CFO -12.8m) / TA 125.4m)
Beneish M = -2.67 (Cap -4..+1) = A
What is the price of STIM shares?

As of August 07, 2026, the stock is trading at USD 2.25 with a total of 782,116 shares traded. Over the past week, the price has changed by +3.10%, over one month by +2.31%, over three months by -2.21% and over the past year by -63.56%.

Current recommended Stop Loss: 2.00 (which is 11.1% or 1.3 ATR below the current price).

Is STIM a buy, sell or hold?

Neuronetics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy STIM.

  • StrongBuy: 1
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the STIM price?
Analysts Target Price 4.5 100%
Neuronetics (STIM) - Fundamental Data Overview as of 07 August 2026
Market Cap USD = 163.5m (163.5m USD * 1.0 USD.USD)
P/S = 1.0784
P/B = 10.3608
Revenue TTM = 151.6m USD
EBIT TTM = -29.0m USD
EBITDA TTM = -25.7m USD
Long Term Debt = 61.3m USD (from longTermDebt, last quarter)
Short Term Debt = 5.42m USD (from shortTermDebt, last quarter)
Debt = 109.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 24.1m
Net Debt = 96.3m USD (calculated: Debt 109.5m - CCE 13.2m)
Enterprise Value = 259.8m USD (163.5m + Debt 109.5m - CCE 13.2m)
Interest Coverage Ratio = -3.45 (Ebit TTM -29.0m / Interest Expense TTM 8.41m)
EV/FCF = -19.13x (Enterprise Value 259.8m / FCF TTM -13.6m)
FCF Yield = -5.23% (FCF TTM -13.6m / Enterprise Value 259.8m)
FCF Margin = -8.96% (FCF TTM -13.6m / Revenue TTM 151.6m)
Net Margin = -24.48% (Net Income TTM -37.1m / Revenue TTM 151.6m)
Gross Margin = 47.96% ((Revenue TTM 151.6m - Cost of Revenue TTM 78.9m) / Revenue TTM)
Gross Margin QoQ = 46.89% (prev 51.95%)
Tobins Q-Ratio = 2.07 (Enterprise Value 259.8m / Total Assets 125.4m)
Interest Expense / Debt = 7.69% (Interest Expense 8.41m / Debt 109.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -22.9m (EBIT -29.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.67 (Total Current Assets 47.2m / Total Current Liabilities 28.3m)
Debt / Equity = 8.25 (Debt 109.5m / totalStockholderEquity, last quarter 13.3m)
 Debt / EBITDA = -3.75 (negative EBITDA) (Net Debt 96.3m / EBITDA -25.7m)
 Debt / FCF = -7.09 (negative FCF - burning cash) (Net Debt 96.3m / FCF TTM -13.6m)
 Total Stockholder Equity = 22.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.76% (Net Income -37.1m / Total Assets 125.4m)
RoE = -164.7% (Net Income TTM -37.1m / Total Stockholder Equity 22.5m)
RoCE = -34.60% (EBIT -29.0m / Capital Employed (Equity 22.5m + L.T.Debt 61.3m))
 RoIC = -24.12% (negative operating profit) (NOPAT -22.9m / Invested Capital 95.0m)
 WACC = 8.74% (E(163.5m)/V(273.0m) * Re(10.53%) + D(109.5m)/V(273.0m) * Rd(7.69%) * (1-Tc(0.21)))
Discount Rate = 10.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.70 | Cagr: 47.45%
 [DCF] Fair Price = unknown (Cash Flow -13.6m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.26 | # QB: 0
Revenue Correlation: 91.37 | Revenue CAGR: 37.39% | SUE: 0.14 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.12 | Chg30d=+0.65% | Revisions=+40% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.11 | Chg30d=+0.71% | Revisions=+25% | Analysts=4
EPS current Year (2026-12-31): EPS=-0.47 | Chg30d=-0.37% | Revisions=+40% | GrowthEPS=+21.2% | GrowthRev=+8.0%
EPS next Year (2027-12-31): EPS=-0.34 | Chg30d=-0.24% | Revisions=+40% | GrowthEPS=+27.4% | GrowthRev=+10.0%
[Analyst] Revisions Ratio: +70% (up=7, down=0)